3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
45
Endometrial Neoplasms
10
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Progesterone Resistance
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Endometrial Hyperplasia
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Obesity
1
Neoplasms by Site
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Infertility, Female
1
Infertility
1
Interventions
Oxaliplatin
5
Mitomycin
4
Hyperthermic Intraperitoneal Chemotherapy
4
Fluorouracil
4
Cisplatin
4
Paclitaxel
3
Doxorubicin
3
Standard of Care
2
Leucovorin
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
sodium thiosulfate
1
relacorilant
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
X-Rays
1
Topotecan
1
Specimen Handling
1
Practice Guidelines as Topic
1
Platinum
1
Pancreatectomy
1
Pafolacianine
1
Observation
1
Mitozytrex
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Laparoscopy
1
LY-2157299
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Peritoneal Neoplasms
×
Letrozole
×
Clear all
NCT04111978
2025-09-29
MATAO
Swiss GO Trial Group
Phase 3
Recruiting
540 enrolled